84 / 89
84
dose cyclophosphamide plus GM-CSF vs. G-CSF alone.
Bone Marrow Transplant 1997;20:211-7.
51.
Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D,
Fassas A, et al. Comparable engraftment kinetics
following peripheral-blood stem-cell infusion mobilized
with granulocyte colony-stimulating factor with or
without cyclophosphamide in multiple myeloma. J Clin
Oncol 1998;16:1547-53.
52.
Nakasone H, Kanda Y, Ueda T, Matsumoto K, Shimizu N,
Minami J, et al. Retrospective comparison of mobilization
methods for autologous stem cell transplantation in
multiple myeloma. Am J Hematol 2009;84:809-14.
53.
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella
V, Callea V, et al. Oral melphalan and prednisone
chemotherapy plus thalidomide compared with
melphalan and prednisone alone in elderly patients with
multiple myeloma: randomized controlled trial. Lancet
2006;367:825-31.
54.
Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone
A, Callea V, et al. Oral melphalan, prednisone, and
thalidomide in elderly patients with multiple myeloma:
updated results of a randomized controlled trial. Blood
2008;112:3107-14.
55.
Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L,
Doyen C, et al. Efficacy of melphalan and prednisone plus
thalidomide in patients older than 75 years with newly
diagnosed multiple myeloma: IFM 01/01 trial. J Clin
Oncol 2009;27:3664-70.
56.
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L,
Björkstrand B, et al. Melphalan and prednisone plus
thalidomide or placebo in elderly patients with multiple
myeloma. Blood 2010;116:1405-12.
57.
Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H,
Aydogdu I, Konuk N, et al. Addition of thalidomide to